# Tendyne Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tendyne-holdings

- Industry: Medical Devices & Equipment
- Headquarters: Roseville, US
- Website: www.tendyne.com
- Total disclosed funding: $4M
- Latest round: Series C (Apr 9, 2014)
- Investors on record: 1

## About

Tendyne Holdings develops innovative medical devices specifically designed for structural heart disease treatments, focusing on advanced therapies to enhance patient care.Tendyne Holdings was founded in 2010 in Roseville, US, and specializes in structural heart disease solutions. In September 2015, Abbott Laboratories acquired Tendyne for USD 250 mn. The company has completed 5 deals until now, with its most recent deal on September 8, 2015. The acquisition marked a significant shift in Tendyne's operational strategy, bringing it under Abbott's expansive portfolio. The firm has no known subsidiaries or parent companies, nor was it formed through a merger or carve-out. The founder's history is not publicly detailed.Tendyne Holdings offers a range of advanced medical devices targeting cardiovascular conditions, particularly structural heart diseases. Their notable products include the MitraClip for mitral valve repair and Tendyne for mitral valve replacement, alongside various Amplatzer devices addressing congenital heart defects. The firm serves healthcare professionals and institutions, focusing on improving patient outcomes in North America, Europe, and select regions in Asia by providing innovative heart therapies.Tendyne Holdings generates revenue primarily through the sale of its structural heart devices to healthcare providers and surgical centers. Transactions occur on a B2B basis, where institutions procure devices either as individual purchases or through partnerships. The revenue stream includes flagship products such as the MitraClip and the Tendyne valve, reflecting their significance in surgical settings and reinforcing their presence in the market.Following the acquisition by Abbott Laboratories, Tendyne Holdings will leverage the USD 250 mn investment to enhance its product development, particularly focusing on new offerings in structural heart solutions. The company is expected to expand its market reach into Europe and Asia by 2025, aiming to introduce innovative devices that align with regulatory milestones. The funding will support research and development initiatives, ensuring that Tendyne remains at the forefront of advancing medical therapies.

## Funding rounds

- Series C, Apr 9, 2014, $4M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series C